Vertex Pharmaceuticals
VRTX
1,072 hedge funds and large institutions have $60.8B invested in Vertex Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 150 funds opening new positions, 417 increasing their positions, 374 reducing their positions, and 102 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 9 → 24 (+15)
47% more first-time investments, than exits
New positions opened: 150 | Existing positions closed: 102
21% more capital invested
Capital invested by funds: $50.2B → $60.8B (+$10.6B)
11% more repeat investments, than reductions
Existing positions increased: 417 | Existing positions reduced: 374
4% more funds holding
Funds holding: 1,034 → 1,072 (+38)
1.85% more ownership
Funds ownership: 90.57% → 92.43% (+1.9%)
32% less call options, than puts
Call options by funds: $591M | Put options by funds: $867M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$970M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$364M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$272M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$153M |
| 5 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
+$140M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$451M |
| 2 |
Man Group
London,
United Kingdom
|
-$126M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$120M |
| 4 |
Jennison Associates
New York
|
-$103M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$98.8M |
VRTX Hedge Fund Activity: Q1 2022 in Review
1,072 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2022, worth a combined $60.8B — up 21% from $50.2B a quarter earlier.
Buyers outnumbered sellers: 150 funds opened new VRTX positions and 102 closed out — a net gain of 48 holders — while 417 added to existing stakes and 374 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $970M. The largest seller was Capital International Investors, cutting an estimated $451M.
- 1,072 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2022, up from 1,034 in Q4 2021.
- Funds reported $60.8B of Vertex Pharmaceuticals stock for Q1 2022, up 21% quarter-over-quarter.
- 150 funds opened new Vertex Pharmaceuticals positions in Q1 2022 and 102 closed out, a net change of +48 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2022 was Fidelity Investments, an estimated $970M added.
- The largest Vertex Pharmaceuticals seller in Q1 2022 was Capital International Investors, an estimated $451M sold.
Based on aggregated 13F filings for Q1 2022.